
Mirabegron Uses, Side Effects & Warnings - Drugs.com
Mar 26, 2025 · Mirabegron is used in adults to treat overactive bladder with symptoms of frequent or urgent urination and urinary incontinence. Mirabegron is sometimes used together with …
Mirabegron - Wikipedia
Mirabegron is the first clinically available beta-3 agonist with approval for use in adults with overactive bladder.
Mirabegron - StatPearls - NCBI Bookshelf
Aug 28, 2023 · Mirabegron, a beta-3 adrenoceptor agonist, has been shown to have high safety and efficacy profile by large random placebo-controlled clinical trials. Mirabegron is used to …
Myrbetriq (mirabegron) - Uses, Side Effects, and More - WebMD
Dec 6, 2023 · Myrbetriq (mirabegron) is commonly used for the following conditions. Overactive Bladder. Overactive bladder, or OAB, is a condition that makes you feel like you need to pee …
begron represent the first approved drug in this new class. It acts by direct relaxation of detrusor smooth muscle via stimulation of bladder β3-adrenoreceptors. In USA and Canada, the …
Mirabegron is the irst beta -3 ago-‐nist approved for the treatment of OAB.10 This article will overview the pharmacology, pharmacokinetics, clinical trials, adverse events, and dosing of …
Mirabegron: Side Effects, Dosage, Uses, and More - Healthline
Feb 28, 2019 · Mirabegron comes as an extended-release tablet that you take by mouth. Mirabegron is used to treat the symptoms of overactive bladder (OAB). It may be prescribed …
For many years, the only available pharmacological treatment for OAB were the antimuscarinic agents. More recently, mirabegron, a selective agonist of the β3 adrenergic receptor, has …
Mirabegron: View Uses, Side Effects and Medicines | 1mg
Mirabegron is used in the treatment of Overactive bladder (OAB) symptoms. OAB is a collection of urinary symptoms, including frequent urination, urgent need to urinate, and inability to …
Mirabegron | Drugs | BNF | NICE
View mirabegron information, including dose, uses, side-effects, renal impairment, pregnancy, breast feeding, contra-indications and monitoring requirements.